Jilted by the FDA in a previous attempt to win approval for its treatment for a fatal lung-scarring disease, InterMune Inc.said it has started a new Phase III study of its drug, called Esbriet.
The Brisbane company (NASDAQ: ITMN) said it enrolled the first patient in a roughly 500-patient trial designed to evaluate the safety and efficacy of Esbriet in people with mild to moderate idiopathic pulmonary fibrosis, or IPF.
No comments:
Post a Comment